Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2.

Interestingly, tucatinib increased ER expression in BT474, and the same trend was noted in MDA-MB-361, although it did not reach statistical significance ( Fig. 1G and H ; Supplementary Fig.

also in 111,027 other papers